drugset / Trial / NCT05737615
PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to find the highest safe dose of hu5B1-TCO and the best dosing schedule of hu5B1-TCO and 64Cu-Tz-SarAr for finding cancer cells that are CA19-9 positive. This study will also help to find out how much radiation the body is exposed to when 64Cu-Tz-SarAr is used, and provide information on the way the body absorbs, distributes, and gets rid of 64Cu-Tz-SarAr.
Timeline
- Start
- 2023-02-10
- Primary completion
- 2026-02-10
- Completion
- 2026-02-10
Outcome
Outcome not reported
Stopped: “Study tracer is currently unavailable”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 64Cu-Tz-SarAr | Diagnostic / imaging agent | — | Intravenous |
| Subject | hu5B1-TCO | Protein / enzyme biologic | — | Intravenous |